BioSpace News Archive

BioMidwest

ESMO 2019: Breast and ovarian cancer drug outperforms targeted hormone therapy in some men with advanced prostate cancer

A drug used for breast and ovarian cancer is more effective than modern targeted hormone treatments at slowing progression and improving survival in some men with advanced prostate cancer, phase III clinical trial findings reveal.

October 1, 2019
·
6 min read
Deals

Arctoris Ltd Secures Seed Funding of £3.2 Million to Advance Novel Drug Discovery Platform Powered by Robotics

Arctoris Ltd, a fully automated drug discovery platform for virtual and traditional biotechnology companies, pharmaceutical corporations and academia, announced that it has successfully closed a seed funding round of £3.2 million to advance its novel drug discovery offering.

October 1, 2019
·
3 min read
Drug Development

Evgen Pharma - ESMO presentation of Phase II STEM clinical data

Evgen Pharma plc announces that the clinical data from the completed open-label Phase II STEM trial was presented in poster format yesterday at the 2019 European Society of Medical Oncology Congress in Barcelona.

October 1, 2019
·
2 min read
FDA

Janssen’s Invokana Becomes First Drug Approved in 20 Years to Slow Diabetic Kidney Disease

Janssen’s Invokana snagged another regulatory approval to reduce the risk of end-stage kidney disease, cardiovascular death and worsening of kidney function in adults with type 2 diabetes and diabetic kidney disease.

October 1, 2019
·
3 min read
·
Alex Keown
Three Retail Pharmacies Suspend Sales of Sanofi’s Zantac

In the wake of the discovery that some Zantac products may contain a carcinogen contaminant due to the manufacturing process, three major drug store retailers in the United States have removed the antacid product from the shelves.

October 1, 2019
·
2 min read
·
Alex Keown
Business

Creoptix Closes Successful Series C Financing Round to Support Further Growth

Creoptix AG announced that is has raised CHF 8 million in the first closing as part of a Series C financing round.

October 1, 2019
·
3 min read
Drug Development

Data from Agios’ Phase 3 ClarIDHy Trial of TIBSOVO® Demonstrates Significant Improvement in Progression Free Survival (PFS) Compared to Placebo in Previously Treated IDH1 Mutant Cholangiocarcinoma Patients

TIBSOVO® Reduced the Risk of Disease Progression or Death by 63% (HR=0.37, p<0.001); Median PFS for Patients Randomized to TIBSOVO® was 2.7 months Compared to 1.4 Months with Placebo

October 1, 2019
·
13 min read
Drug Development

Data From Randomized Phase 2 ENTRATA Study Demonstrate Telaglenastat with Everolimus Improves Progression-Free Survival in Renal Cell Carcinoma

Data shared in oral presentation at ESMO Congress 2019 show telaglenastat doubles median progression-free survival (PFS) in heavily pre-treated patients with advanced disease, reduced risk of death by 36% (HR=0.64, p=0.079 one-sided)

October 1, 2019
·
8 min read
Drug Development

Chi-Med to Discuss Surufatinib Phase III and U.S. Phase I/Ib Efficacy and Safety Data Presented at the 2019 ESMO Annual Meeting

Hutchison China MediTech Limited presented the results of the Phase III study of surufatinib in advanced neuroendocrine tumors – extra-pancreatic at the 2019 European Society for Medical Oncology Congress.

October 1, 2019
·
11 min read
Policy

Adocia Announces Receipt of USD 14.3 million Payment from Eli Lilly Following Arbitration Conclusion and the Decision by Mutual Consent with Eli Lilly to Conclude the Civil Case

The payment of USD 14.3 million corresponds to the USD 11.6 million in damages plus interest awarded to Adocia in August 2018 by an American Arbitration Association Panel presiding over Adocia’s arbitration claims against Eli Lilly

October 1, 2019
·
5 min read